Virtus ETF Advisers’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Virtus ETF Advisers’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-9,954	Closed	-$66.4K	–	470
2023 Q3	$66.4K	Sell	9,954 -985	-9%	-$8.19K	0.04%	392
2023 Q2	$99.1K	Sell	10,939 -3,963	-27%	-$35K	0.06%	385
2023 Q1	$108K	Sell	14,902 -5,727	-28%	-$42.5K	0.06%	332
2022 Q4	$150K	Buy	20,629 +5,494	+36%	+$40.8K	0.08%	344
2022 Q3	$117K	Buy	15,135 +106	+0.7%	+$900	0.05%	404
2022 Q2	$102K	Buy	+15,029	New	+$115K	0.04%	426

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Virtus ETF Advisers's PNT Position: Q4 2023 in Review

Virtus ETF Advisers sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 9,954 shares — an estimated $66.4K sold.

Virtus ETF Advisers first reported a position in PNT in Q2 2022 and held it in 6 quarters. The position peaked at $150K in Q4 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Virtus ETF Advisers reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Virtus ETF Advisers sold 9,954 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $66.4K.
Virtus ETF Advisers first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2022 and held it in 6 quarters.
Virtus ETF Advisers's POINT Biopharma Global Inc. Common Stock position peaked at $150K in Q4 2022.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Virtus ETF Advisers's 13F filing for Q4 2023, filed 15 Feb 2024.